CoChat

HIF1α is not a target of 14q deletion in clear cell renal cancer

Open access
Shenoy, Niraj · 2020 · Scientific Reports

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

HIF1α has been termed a tumor-suppressor in clear cell renal cell carcinoma (ccRCC), primarily based on functional proliferation studies in cell lines (in vitro and in vivo) with genetic manipulation, and the adverse prognosis of 14q-deleted ccRCC patients. In other malignancies, however, HIF1α has an established tumor-promoting role. Therefore, this study sought to further examine the role of HIF1α in ccRCC using bioinformatic analyses of 530 ccRCC patients from The Cancer Genome Atlas (TCGA) and The Cancer Proteome Atlas (TCPA) registries. Although lower copy numbers of HIF1A (encoding HIF1α, located at 14q23.2) was associated with worse survival, there was no survival difference based on either HIF1A mRNA or HIF1α protein expression. Interestingly, L2HGDH (L-2-Hydroxyglutarate Dehydrogenase), a recently characterized epigenetic modulating ccRCC tumor-suppressor with a marked impact on survival, was found to be located only ~ 11.5Mbp from HIF1A on 14q (at 14q21.3). L2HGDH was therefore co-deleted in ~ 95% of 14q deletions involving HIF1A locus. Remarkably, HIF1A CNV had a markedly stronger correlation with L2HGDH expression (Rho = 0.55) than its own gene expression (Rho = 0.27), indicating high preserved-allele compensation of HIF1A. Genetic loss of HIF1A was therefore associated with a much greater reduction of L2HGDH gene expression than its own gene expression, providing a possible explanation for survival differences based on HIF1A CNV and mRNA expression. Furthermore, in 14q-deleted ccRCC patients with complete (uncensored) survival data, in the relatively rare cases where genetic loss of HIF1A occurred without genetic loss of L2HGDH (n = 5), the survival was significantly greater than where there was simultaneous genetic loss of both (n = 87) (mean survival 1670.8 ± 183.5 days vs 885.1 ± 78.4 days; p = 0.007). In addition, there was no correlation between HIF1A mRNA and HIF1α protein expression in ccRCC (R = 0.02), reflecting the primarily post-translational regulation of HIF1α. Lastly, even between L2HGDH and HIF1A loci, 14q was found to have several other yet-to-be-characterized potential ccRCC tumor-suppressors. Taken together, the data indicate that HIF1α is not a target of 14q deletion in ccRCC and that it is not a tumor-suppressor in this malignancy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-74631-7

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Survival analyses in ccRCC (TCGA) based on HIF1A CNV, HIF1A mRNA expression, HIF1α protein and CA9 protein expression. (A) Lower HIF1A CNV (< -0.0297 log2(copy-number/2)) in primary ccRCC tumors was associated with worse overall survival than higher HIF1A CNV (≥ -0.0297 log2(copy-number/2)) (log-rank test p = 0.01, n = 531, TCGA clear cell RCC). (B) However, there was no significant difference in survival between ccRCC patients with lower HIF1A mRNA expression in primary tumors (< 19.4 log2(fpkm-uq + 1)) and higher HIF1A mRNA expression (≥ 19.4 log2(fpkm-uq + 1)) (log-rank test p = 0.33, n = 530, TCGA clear cell RCC). Fpkm-uq (Fragments per kilobase of transcript per million mapped reads- upper quartile) is an RNA-sequencing-based expression normalization method. (C) Similarly, no significant survival difference between ccRCC patients with lower HIF1α protein expression and higher HIF1α protein expression based on Reverse Phase Protein Array functional proteomics (log-rank test p = 0.4, n = 444, The Cancer Proteome Atlas). (D) Also, no significant survival difference between ccRCC patients with lower CA9 protein expression and higher CA9 protein expression (log-rank test p = 0.4, n = 444). In fact, the curves separated beyond ~ Day 2500 and at Day 4000, the higher CA9 expression group had a lower survival rate of 28% compared to that of 51% in the lower CA9 expression group.
Figure 1 Survival analyses in ccRCC (TCGA) based on HIF1A CNV, HIF1A mRNA expression, HIF1α protein and CA9 protein expression. (A) Lower HIF1A CNV (< -0.0297 log2(copy-number/2)) in primary ccRCC tumors was associated with worse overall survival than higher HIF1A CNV (≥ -0.0297 log2(copy-number/2)) (log-rank test p = 0.01, n = 531, TCGA clear cell RCC). (B) However, there was no significant difference in survival between ccRCC patients with lower HIF1A mRNA expression in primary tumors (< 19.4 log2(fpkm-uq + 1)) and higher HIF1A mRNA expression (≥ 19.4 log2(fpkm-uq + 1)) (log-rank test p = 0.33, n = 530, TCGA clear cell RCC). Fpkm-uq (Fragments per kilobase of transcript per million mapped reads- upper quartile) is an RNA-sequencing-based expression normalization method. (C) Similarly, no significant survival difference between ccRCC patients with lower HIF1α protein expression and higher HIF1α protein expression based on Reverse Phase Protein Array functional proteomics (log-rank test p = 0.4, n = 444, The Cancer Proteome Atlas). (D) Also, no significant survival difference between ccRCC patients with lower CA9 protein expression and higher CA9 protein expression (log-rank test p = 0.4, n = 444). In fact, the curves separated beyond ~ Day 2500 and at Day 4000, the higher CA9 expression group had a lower survival rate of 28% compared to that of 51% in the lower CA9 expression group.CC BY · PubMed Central
Figure 2 (A) Depiction of L2HGDH, a recently characterized epigenetic modulating ccRCC tumor suppressor gene with a marked impact on survival, located only ~ 11.5Mbp from HIF1A on 14q. (B) Heatmap to visualize the relationship between HIF1A CNV, L2HGDH CNV, HIF1A gene expression, L2HGDH gene expression in primary ccRCC tumors. The heatmap reveals that there is very strong correlation between HIF1A CNV and L2HGDH CNV, and that HIF1A CNV appears to correlate stronger with L2HGDH gene expression rather than its own gene expression. (TCGA clear cell RCC, n = 530). (C–F) Scatter plots showing the strength of correlation between (C) HIF1A CNV and L2HGDH CNV; (D) HIF1A CNV and HIF1A mRNA expression; (E) HIF1A CNV and L2HGDH mRNA expression; (F) HIF1A mRNA and HIF1α protein expression; in ccRCC primary tumors (TCGA and TCPA clear cell RCC). Spearman’s rank Rho values and Pearson’s correlation R value are as indicated. The strength of correlation between HIF1A CNV and L2HGDH mRNA expression was 2-times that between HIF1A CNV and HIF1A mRNA expression, indicating high preserved allele compensation of HIF1A. Furthermore, there was no correlation between HIF1A mRNA and HIF1α protein expression.
Figure 2 (A) Depiction of L2HGDH, a recently characterized epigenetic modulating ccRCC tumor suppressor gene with a marked impact on survival, located only ~ 11.5Mbp from HIF1A on 14q. (B) Heatmap to visualize the relationship between HIF1A CNV, L2HGDH CNV, HIF1A gene expression, L2HGDH gene expression in primary ccRCC tumors. The heatmap reveals that there is very strong correlation between HIF1A CNV and L2HGDH CNV, and that HIF1A CNV appears to correlate stronger with L2HGDH gene expression rather than its own gene expression. (TCGA clear cell RCC, n = 530). (C–F) Scatter plots showing the strength of correlation between (C) HIF1A CNV and L2HGDH CNV; (D) HIF1A CNV and HIF1A mRNA expression; (E) HIF1A CNV and L2HGDH mRNA expression; (F) HIF1A mRNA and HIF1α protein expression; in ccRCC primary tumors (TCGA and TCPA clear cell RCC). Spearman’s rank Rho values and Pearson’s correlation R value are as indicated. The strength of correlation between HIF1A CNV and L2HGDH mRNA expression was 2-times that between HIF1A CNV and HIF1A mRNA expression, indicating high preserved allele compensation of HIF1A. Furthermore, there was no correlation between HIF1A mRNA and HIF1α protein expression.CC BY · PubMed Central
Figure 3 (A) Genetic loss (shallow deletions) of HIF1A was associated with a much greater reduction of L2HGDH expression than its own gene expression (TCGA ccRCC, cbioportal). (B) Survival based on L2HGDH expression with the same dataset (TCGA ccRCC, n = 530). Higher L2HGDH expression (≥ 15.16 log2(fpkm-uq + 1)) was associated with significantly improved survival (log-rank p value as depicted). (C) In ccRCC patients with complete (uncensored) survival data (TCGA), patients with “HIF1A shallow deletion + L2HGDH diploid” had significantly greater mean survival (1670.8 days + /- 183.5 days, n = 5) compared to patients with “HIF1A shallow deletion + L2HGDH shallow deletion” (885.1 days + /- 74.3 days, n = 87) (t-test p value = 0.007). Data represented as means ± s.e.m. (D) Kaplan Meier survival curves of the two groups showing a wide separation between the curves (Peto and Peto modification of the Gehan- Wilcoxon test ‘p’ value = 0.033). Put together, when genetic loss of HIF1A occurs without genetic loss of L2HGDH in ccRCC, the survival is significantly greater than when there is simultaneous genetic loss of HIF1A and L2HGDH, which argues against HIF1A being a target of 14q deletion, and against HIF1A being a 14q tumor-suppressor in ccRCC.
Figure 3 (A) Genetic loss (shallow deletions) of HIF1A was associated with a much greater reduction of L2HGDH expression than its own gene expression (TCGA ccRCC, cbioportal). (B) Survival based on L2HGDH expression with the same dataset (TCGA ccRCC, n = 530). Higher L2HGDH expression (≥ 15.16 log2(fpkm-uq + 1)) was associated with significantly improved survival (log-rank p value as depicted). (C) In ccRCC patients with complete (uncensored) survival data (TCGA), patients with “HIF1A shallow deletion + L2HGDH diploid” had significantly greater mean survival (1670.8 days + /- 183.5 days, n = 5) compared to patients with “HIF1A shallow deletion + L2HGDH shallow deletion” (885.1 days + /- 74.3 days, n = 87) (t-test p value = 0.007). Data represented as means ± s.e.m. (D) Kaplan Meier survival curves of the two groups showing a wide separation between the curves (Peto and Peto modification of the Gehan- Wilcoxon test ‘p’ value = 0.033). Put together, when genetic loss of HIF1A occurs without genetic loss of L2HGDH in ccRCC, the survival is significantly greater than when there is simultaneous genetic loss of HIF1A and L2HGDH, which argues against HIF1A being a target of 14q deletion, and against HIF1A being a 14q tumor-suppressor in ccRCC.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 15

Metadata

Authors
Shenoy, N.
Affiliations
Albert Einstein College of Medicine (US)
Corresponding author
Shenoy, Niraj
Venue
Scientific Reports
Published
2020-10-19
Volume
10
Issue
1
Pages
17642-17642
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3092968756
Cited by
14
References
59
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5
FWCI
1.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Albert Einstein Cancer Center (2P30CA013330-47)
Topics
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
clear cell renal cell carcinoma, HIF-1α, 14q deletion, copy number variation, tumor suppressor, tumor promoters, gene expression, survival, prognostic factors, epigenetic regulation, TCGA, tcpA
MeSH terms
Carcinoma, Renal Cell, Chromosome Deletion, Chromosomes, Human, Pair 14, Female, Humans, Kidney Neoplasms, Male, Prognosis, Registries, Gene Expression Regulation, Neoplastic, Survival Rate, Genes, Tumor Suppressor, Computational Biology, Databases, Genetic, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HIF1α is not a target of 14q deletion in clear cell renal cancer. https://app.cochat.ai/papers/10.1038/s41598-020-74631-7
The paper
Shenoy, N. (2020). HIF1α is not a target of 14q deletion in clear cell renal cancer. Scientific Reports. https://doi.org/10.1038/s41598-020-74631-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.